2002, Number 4
<< Back Next >>
Gac Med Mex 2002; 138 (4)
Mechanisms for pregnancy termination. A Review of the Literature and Its Potential Role in Mexico and Latin America.
Espinoza H, Ellertson C, García S, Schiavon R, Langer A
Language: Spanish
References: 78
Page: 347-356
PDF size: 65.32 Kb.
ABSTRACT
In this document, we review the relevant aspects of the different medical methods of abortion. We describe the principal medical regimens currently used in North America, Europe, and a growing number of developing countries. We also describe specific treatment regimens (which usually involve a combination of two drugs), physiological methods of action, potential side effects and complications, method requirements, including follow-up visits, any existing contraindication, and acceptability of these methods among patients. Finally, we comment on the potential role of medical abortion in Mexico and throughout Latin America.
REFERENCES
1. Riddle J. Contraception and abortion from the ancient world to the renaissance. Cambridge, MA. USA: Harvard University Press; 1992.
2. Amuchastegui A. Virginidad e iniciación sexual en México: experiencias y significados. México: Edamex; 2001.
3. WHO. Safe motherhood. A newsletter of worldwide activity (28). Geneva, Switzerland: World Health Organization; 2000.
4. Thiersch J. Therapeutic abortions with a folic acid antagonist, 4-aminopteroylglutamic acid (4-Amino P.G.A.) administered by the oral route. Am J Obstet Gynecol 1952;63:1298-1304.
5. Newhall E, Winikoff B. Abortion with mifepristone and misoprostol: regimens, efficacy, acceptability and future directions. Am J Obstet Gynecol, 2000;183(2):S44-S53.
6. Grimes D. Medical abortion: public health and private life. Am J Obstet Gynecol 2000;183(2):S1-S2.
7. Swahn M, Bygdeman M. Progesterone receptor blockage. Effect on uterine contractility and early pregnancy. Contraception 1985;32(1):45-51.
8. Mifepristone: a chronology. Momentum. News from the Population Council. New York: Population Council; January 2001.
9. Creinin M, Darney P. Methotrexate and misoprostol for early abortion. Contraception 1993;48(4):339-348.
Norman J, Thong K, Baird D. Uterine contractility and induction of abortion in early pregnancy by misoprostol and mifepristone. Lancet 1991;338:1233-1236.
Moore K, Persaud T. Embriología clínica [Clinical embriology]. 6th Spanish ed., 2000. Mc Graw-Hill Intera-mericana. 1998.
Herrmann W, Wyss R, Riondel A, Philibert D, Teutsch G, Sakiz E, Baulieu E. Effect d'un stéroid anti-progesterone chez la femme: interruption du cycle menstruel et de la grosesse au debut. CR Acad Sci Paris 1992;294:993-938.
Kovacs L, Sas M, Resch B, Ugocsai G, Swahn M, Bygdeman M, Rowe P. Termination of pregnancy by RU486 - an antiprogestational compound. Contraception 1984;29:399-410.
Hertzen H. Research on regimens for early medical abortion. J Am Med Womens Assoc 2000;55(3):133-136.
DeLoia J, Stewart-Akers A, Creinin M. Effects of methotrexate on trophoblast proliferation and local immune responses. Hum Reprod 1998;13:1063-1069.
Creinin M, Vittinghoff E, Galbraith S, Klaisle C. A randomized controlled trial comparing misoprostol 3 and 7 days following methotrexate for early abortion. Am J Obstet Gynecol 1995;173:1578-1584.
Creinin M. Medical abortion with methotrexate 75 mg IM and vaginal misoprostol. Contraception 1998;56:367-371.
Carbonell J, Velazco A, Varela L, Cabezas E, Fernández C, Sánchez C. Misoprostol 3, 4, or 5 days after methotrexate for early abortion. Contraception 1997;56(3):321-327.
Peyron R, Aubéniz E, Tragos V, Silvestre L, Renault M, Elkik F, Leclerc P, Ulmann A, Baulieu E. Early termination of pregnancy with mifepristone (RU 486) and the orally active prostaglandin misoprostol. N Engl J Med 1993;328:1509-1513.
Schaff E, Fielding S, Westhoff C, Ellertson C, Eisinger S, Stadalius L, Fuller L. Vaginal misoprostol administered 1, 2 or 3 days after mifepristone for early medical abortion: a randomized trial. JAMA 2000;284(15):1948-1953.
Danielsson K, Marions L, Rodríguez A, Spur B, Wong P, Bygdeman M. Comparison between oral and vaginal administration of misoprostol on uterine contractility. Obstet Gynecol 1999;93:275-280.
Toppozada M, Anwar M, Hassan H, el-Gazaerly W. Oral or vaginal misoprostol for induction of labor. Int J Gynaecol Obstet 1997;56:135-139.
Alastair J, Wood M, editors. Misoprostol and pregnancy. N Engl J Med 2001;344:38- 47.
Creinin M, Pymar H. Medical abortion alternatives to mifepristone. J Am Med Womens Assoc 2000;55(3):127-132.
Creinin M, Aubény E. Medical abortion in early pregnancy. In: Paul M, Lichtenberg E, Borgatta L, Grimes D, Stubblefield P., editors. A clinician's guide to medical and surgical abortion. New York: Churchill Livingstone; 1999. p. 91-106.
Baird D. Mode of action of medical methods of abortion. J Am Med Womens Assoc 2000;55(3):121-126.
Creinin M. (2000). Medical abortion regimens: historical context and overview. Am J Obstet Gynecol 1999;183(2):S3-S9.
Physician's desk reference. 1999.
Karim S. Once a month vaginal administration of prosta-glandin E2 and F2? for fertility control. Contraception, 1971;3:173-183.
Mocsary P, Csapo, A. Menstrual induction with PGF2? and PGE2. Prostaglandins 1975;10:545-547.
Blanchard K, Winikoff B, Coyaji K, Nguyen N. Misoprostol alone: a new method of medical abortion? J Am Med Womens Assoc 2000;55(3):186-188.
Grimes D, Schulz, K, Cates W Jr. Prevention of uterine perforation during curettage abortion. JAMA 1984;251: 2108-2111.
Schulz K, Grimes D, Cates W Jr. Measures to prevent cervical injury during suction curettage abortion. Lancet 1983;1(8335):1182-1185.
El-Rafaey H, Calder H, Wheatley D, Templeton A. Cervical priming with prostaglandin E1 analogues, misoprostol and gemeprost. Lancet, 1994;343:1207-1209.
MacIsaac L, Grossman D, Balistreri, E, Darney P. A randomized controlled trial of laminaria, oral misoprostol, and vaginal misoprostol before abortion. Obstet Gynecol 1999;93:766-770.
Singh K, Fong Y, Prasad R, Dong F. Randomized trial to determine optimal dose of vaginal misoprostol for preabortion cervical priming. Obstet Gynecol 1998;92:795-8.
Bamigboye A, Hofmeyr G, Merrell D. Rectal misoprostol in the prevention of postpartum hemorrhage: a placebo-controlled trial. Am J Obstet Gynecol 1998;179:1043-1046.
O'Brien P, El-Rafaey H, Gordon A, Geary M, Rodeck C. Rectally administered misoprostol for the treatment of postpartum hemorrhage unresponsive to oxytocin and ergometrine: a descriptive study. Obstet Gynecol 1998;92: 212-214.
Bugalho A, Bique C, Machungo F, Faundes A. Induction of labor with intravaginal misoprostol in intrauterine fetal death. Am J Obstet Gynecol 1994;171:538-541.
Wing D, Ortiz-Omphroy G, Paul R. A comparison of intermittent vaginal administration of misoprostol with continuous dinoprostone for cervical ripening and labor induction. Am J Obstet Gynecol 1997;177:612-618.
Paul M, Schaff E, Nichols M. The roles of clinical assessment, human chorionic gonadotropin assays, and ultrasonography in medical abortion practice. Am J Obstet Gynecol 2000;183(2); S34-S43.
Schaff E, Fielding S. A comparison of the Abortion Rights Mobilization and Population Council trials. J Am Med Womens Assoc 2000;55(3):137-141.
MacIsaac L, Darney P. Early medical abortion: an alternative to and backup for medical abortion. Am J Obstet Gynecol 2000;183(2):S76-S83.
Breitbart V, Rogers K, VanDerhei D. Medical abortion service delivery. Am J Obstet Gynecol 2000;183(2);S16-S25.
Kruse B, Poppema S, Creinin M, Paul M. Management of side effects and complications in medical abortion. Am J Obstet Gynecol 2000;183(2):S65-S75.
Breitbart V. Counseling for medical abortion. Am J Obstet Gynecol 2000;183 (2):S26-S33.
Department of Health and Human Services. FDA approves mifepristone for the termination of early pregnancy. http://www.fda.gov/bbs/topics/NEWS/NEW00737.html. Retrieved on February 2001.
Schaff E, Stadalius L, Eisinger S, Franks P. Vaginal misoprostol administered at home after mifepristone (RU 486) for abortion. J Fam Pract 1997;44:353-360.
Spitz I, Bardin W, Benton L, Robbins A. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med, 1998;338:1241-1247.
Joffe, C. Medical abortion in social context. Am J Obstet Gynecol 2000;183(2):S10-S15.
Creinin M, Vittinghoff E, Schaff E, Klaisle C, Darney P, Dean C. Medical abortion with oral methotrexate and vaginal misoprostol. Obstet Gynecol 1997;90:611-616.
Carbonell J, Varela L, Velazco L, Cabezas E, Fernández C, Sánchez C. Oral methotrexate and vaginal misoprostol for early abortion. Contraception 1998;57:83-88.
Creinin M. Randomized comparison of efficacy, acceptability and cost of medical versus surgical abortion. Contraception 2000;62:117-124.
Khan J, Becker B, MacIsaac L, Amory J, Neuhaus J, Olkin I, Creinin M. The efficacy of medical abortion: A meta-analysis. Contraception 2000;61:29-40.
Hausknecht R. Methotrexate and misoprostol to terminate early pregnancy. N Engl J Med 1995;333:537-540.
Creinin M, Vittinghoff E. Keder L, Darney P, Tiller G. Methotrexate and misoprostol for early abortion: a multicenter trial. Safety and efficacy. Contraception 1996;53: 321-327.
Stewart F. Improving early options for abortion: it's time to stop waiting. J Am Med Womens Assoc 2000;55(3):115-116.
Rosing M, Archbald C. The knowledge, acceptability, and use of misoprostol for self-induced medical abortion in an urban US population. J Am Med Womens Assoc 2000;55(3): 183-185.
Carbonell J, Varela L, Velazco A, Fernández, C. The use of misoprostol for termination of early pregnancy. Contraception 1997;55:165-168.
Jain J, Meckstroth K, Mishell D. Early pregnancy termination with intravaginally administered sodium chloride solution-moistened misoprostol tablets: historical comparison with mifepristone and oral misoprostol. Am J Obstet Gynecol 1999;181:1386-1391.
Creinin M, Vittinghoff E. Methotrexate and misoprostol vs misoprostol alone for early abortion: a randomized controlled trial. JAMA 1994;272:1190-1195.
Baker A, Beresford T, Halvorson-Boyd G, Garrity J. Informed consent, counseling and patient preparation. In: Paul M, Lichtenberg E, Borgatta L, Grimes D, Stubblefield P, editors. A clinician's guide to medical and surgical abortion. New York: Churchill Livingstone; 1999. p. 25-37.
Reproductive Health Program. Mifeprex medical abortion: patient information and consent. Rochester, NY, USA: University of Rochester School of Medicine; 2000.
Coyaji K. Early medical in India: three studies and their implications for abortion services. J Am Med Womens Assoc 2000;55(3): 197-199.
Ashok P, Penney G, Flett G, Templeton A. An effective regimen for early medical abortion: a report of 2000 consecutive cases. Hum Reprod 1998;13(10):2962-2965.
World Health Organization. Task Force on Post-Ovulatory Methods of Fertility Regulations. Termination of pregnancy with reduced dosis of mifepristone. Br Med J 1993;307:532-537.
Isaacs J Jr, McGehee R, Cowan B. Life-threatening neutropenia following treatment of ectopic pregnancy: a report of two cases. Obstet Gynecol 1996;88:694-6.
Trout S, Kemmann E. Reversible alopecia after single-dose methotrexate treatment in a patient with ectopic pregnancy. Fertil Steril 1995;64:866-867.
Horrigan T, Fanning J, Marcotte M. Methotrexate pneumonitis after systemic treatment for ectopic pregnancy. Am J Obstet Gynecol 1997;176:714-715.
Ulmann A, Silvestre L, Rezvani Y, Renault M, Aguilaume C, Baulieu E. Medical termination of early pregnancy with mifepristone (RU 486) followed by a prostaglandin analogue: study in 16,369 women. Acta Obstet Gynecol Scand 1992;71(4):278-283.
Winikoff B, Ellertson C, Elul B, Sivin I. Acceptability and feasibility of early pregnancy termination by mifepristone-misoprostol. Arch Fam Med 1998;7:360-366.
Schaff E, Eisinger S, Stadalius L, Franks P, Gore B, Poppema S. Low-dose mifepristone 200 mg and vaginal misoprostol for induced abortion. Contraception 1999; 59(1):1-6.
Elul B, Pearlman E, Sorhaindo A, Simonds W, Westhoff C. In depth interviews with medical abortion clients: thoughts on the method and home administration of misoprostol. J Am Med Womens Assoc 2000;55 (3):169-172.
Clark S, Ellertson C, Winikoff B. Is medical abortion acceptable to all American women: the impact of sociodemographic characteristics on the acceptability of mifepristone-misoprostol abortion. J Am Med Womens Assoc 2000;55 (3):177-188.
Henshaw S. Induced abortion: a world review. Family Plann Perspect 1990;22:76-89.
The Alan Guttmacher Institute. El aborto clandestino: una realidad latinoamericana. New York: The Alan Guttmacher Institute. 1994.
WHO. Unsafe abortion. Global and regional estimates of incidence of and mortality due to unsafe abortion, with a listing of available country data (WHO/RHT/MSM/97). Geneva, Switzerland: World Health Organization; 1998.
GIRE. Aspectos del aborto en México. Grupo de Información sobre Reproducción Elegida. México, D. F: 2000.